AVDL
Avadel Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AVDL
Avadel Pharmaceuticals Plc
A biopharmaceutical company focused on niche branded parmaceutical products in the US
10 Earlsfort Terrace, Dublin 2, Ireland, D02 T380
--
Avadel Pharmaceuticals plc was registered as an Irish private limited company on December 1, 2015 and re-registered as an Irish public limited company on November 21, 2016. Avadel Pharmaceuticals plc is a specialty pharmaceutical company with a long history in drug delivery, focusing on developing safer and more effective formulations that address unmet pharmaceutical needs during research. The company focuses on: (1) the development and licensing of five functional and proprietary drug delivery platforms, (2) the development of novel, high-value products based on drug delivery platforms, and (3) the development, approval and marketing of niche brand and generic products in the United States after the acquisition of Eclat Pharmaceuticals.
Earnings Call
Q1/2025
Estimate EPS-0.07
Actual EPS-0.05
Estimate Revenue50.57M
Actual Revenue52.50M
Avadel Pharmaceuticals' Q1 2025 Earnings Call: Unraveling Contradictions in Patient Strategy and Market Access
May 07,2025 07:24
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS0.03
Actual EPS0.1
Estimate Revenue60.28M
Actual Revenue68.13M
Avadel Pharmaceuticals Q2 2025: Unraveling Contradictions in Revenue Growth and Patient Dynamics
Aug 07,2025 08:43
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
AVDL has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected 0.05, missing expectations. The chart below visualizes how AVDL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AVDL has released its 2025 Q3 earnings report, with revenue of 77.47M, reflecting a YoY change of 54.86%, and net profit of 20.00K, showing a YoY change of 100.76%. The Sankey diagram below clearly presents AVDL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
